{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:39:36Z","timestamp":1780699176694,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"scientific research fund of Shanghai Pharmaceutical Association","award":["2014YY0101, 2015YY0103"],"award-info":[{"award-number":["2014YY0101, 2015YY0103"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Creatine kinase elevation is commonly reported in telbivudine\u2010treated patients. However, little is known about the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC\u2010MS\/MS for the determination of telbivudine in a clinical study of chronic hepatitis B patients. The assay was linear in a dynamic 10\u201310,000 ng\/mL range (r<jats:sup>2<\/jats:sup>&gt; 0.999) and total analysis time was 6 min in this method. The validated method was applied to quantitatively determine plasma concentration in chronic hepatitis B patients during long\u2010term telbivudine treatment. The results revealed that telbivudine concentration in the creatine kinase\u2010elevated group (707.92\u20132788.78 ng\/mL) was significantly higher than those with normal creatine kinase (412.63\u20131108.32 ng\/mL). This method was adapted for therapeutic drug monitoring.<\/jats:p>","DOI":"10.1002\/bmc.4140","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T06:02:35Z","timestamp":1510898555000},"source":"Crossref","is-referenced-by-count":5,"title":["Determination of telbivudine in the plasma of chronic hepatitis B patients in long\u2010term treatment by high\u2010performance liquid chromatographic\u2013tandem mass spectrometry"],"prefix":"10.1002","volume":"32","author":[{"given":"Bicui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-2633","authenticated-orcid":false,"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huashan Hospital Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.03.032"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162760"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1978-9"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-323"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.07.005"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1728-1733.2002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006290623"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.053"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20374"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0004-y"},{"key":"e_1_2_7_13_1","first-page":"119","article-title":"Antiviral beta\u2010l\u2010nucleosides specific for hepatitis B virus infection","volume":"12","author":"Standring D. N.","year":"2001","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00117-13"},{"key":"e_1_2_7_15_1","volume-title":"Guidance for Industry, Bioanalytical Method Validation","author":"US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research","year":"2001"},{"key":"e_1_2_7_16_1","unstructured":"US Food and Drug Administration(2013).\u2009Guidance for Industry \u2013 Bioanalytical Method Validation. Retrieved fromhttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM368107.pdf"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.01.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.12.023"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-202069"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01313-05"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.874-879.2006"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005284849"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1721-1726.2006"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00557-07"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01412.x"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.4140","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.4140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:42:41Z","timestamp":1760038961000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.4140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/bmc.4140"],"URL":"https:\/\/doi.org\/10.1002\/bmc.4140","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]},"article-number":"e4140"}}